AtriCure, Inc. (ATRC)
NASDAQ: ATRC · Real-Time Price · USD
34.19
+1.03 (3.09%)
At close: Nov 19, 2025, 4:00 PM EST
34.18
-0.01 (-0.01%)
After-hours: Nov 19, 2025, 4:10 PM EST
AtriCure Revenue
AtriCure had revenue of $134.27M in the quarter ending September 30, 2025, with 15.84% growth. This brings the company's revenue in the last twelve months to $518.31M, up 15.80% year-over-year. In the year 2024, AtriCure had annual revenue of $465.31M with 16.55% growth.
Revenue (ttm)
$518.31M
Revenue Growth
+15.80%
P/S Ratio
3.14
Revenue / Employee
$398,696
Employees
1,300
Market Cap
1.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 465.31M | 66.06M | 16.55% |
| Dec 31, 2023 | 399.25M | 68.87M | 20.84% |
| Dec 31, 2022 | 330.38M | 56.05M | 20.43% |
| Dec 31, 2021 | 274.33M | 67.80M | 32.83% |
| Dec 31, 2020 | 206.53M | -24.28M | -10.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ATRC News
- 1 day ago - AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 9 days ago - AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 20 days ago - AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025 - Business Wire
- 22 days ago - AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial - Business Wire
- 23 days ago - AtriCure to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - AtriCure to Announce Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation - Business Wire